Athens Medical C.S.A., (IATR) Fair Value & Analysis
Healthcare · GR · Market cap €153M
Fair value as of: Jul 24, 2026
From 4 valuation models · updated 17 days ago
Share price −7.8% over the past month.
Below-average quality, screening 38% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (€1.34 to €3.22) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range €1.25 – €2.30 · fair‑value band €1.34 – €3.22 · the €1.65 price screens below the €2.28 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Athens Medical C.S.A., (IATR) currently trades at €1.65, while our model-based Fair Value estimate is €2.28, implying the stock looks roughly 38.2% undervalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Athens Medical C.S.A., generated revenue of €271M at a net margin of -1.8%. Revenue grew 0.8% year over year. It earns a return on equity of -4.1%. Net debt stands at €129M. Fundamentals as of Jul 24, 2026
Our scenario range runs from €1.34 (bear case) to €3.22 (bull case); at €1.65, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 38%, IATR screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Asset-Based (€0.8000) versus Multiples (€0.4300). Highest evidence: EV/EBITDA (54).
Notify me when IATR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally. The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, …
Full company description
Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally. The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, gynecologic, and urology services; and neuro- and spine surgery services. It also provides medical services for range of orthopedics, such as foot and ankle, hand and wrist, hip, knee, shoulder, and spine; sports injuries; plastic Surgeries for face, body, breast, obesity, reconstructive plastic surgery, scar correction, and sex reassignment; bariatric surgery for gastric banding, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch; and chronic diseases, including diabetes, endocrinology, heat failure, high blood pressure, pain management, respiratory system, stroke, and thyroid conditions. In addition, the company operates wellness and prevention centers; and offers medical education, training, and practice services. The company was founded in 1983 and is based in Athens, Greece.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Athens Medical C.S.A., reported revenue of €276M in FY2025 versus €226M in FY2021, a compound +5.1%/yr. Reported net income was −€4.7M in FY2025.
Watch IATR: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Athens Medical C.S.A., with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Athens Medical C.S.A., (IATR) overvalued or undervalued?
What is the fair value of IATR?
What is the quality score of IATR?
What is the revenue of Athens Medical C.S.A., (IATR)?
What is the net profit margin of IATR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Athens Medical C.S.A., and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.